HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pilot Therapeutics

This article was originally published in The Tan Sheet

Executive Summary

Company retains Quintiles (Research Triangle Park, N.C.) to conduct a randomized, double-blind, placebo-controlled clinical study of Pilot's dietary supplement for asthmatics beginning in the fourth quarter. Resulting data will include information from a rising-dose tolerance study. Winston-Salem, N.C.-based Pilot plans to market the product as inhibiting the production of leukotrienes, which are asthma biomarkers. The supplement contains gammalinolenic acid and a delta-5 desaturase inhibitor (1"The Tan Sheet" July 10, p. 8)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

RS132767

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel